TY - JOUR
T1 - Caffeine – rich infusion from Cola nitida (kola nut) inhibits major carbohydrate catabolic enzymes; abates redox imbalance; and modulates oxidative dysregulated metabolic pathways and metabolites in Fe2+-induced hepatic toxicity
AU - Erukainure, Ochuko L.
AU - Oyebode, Olajumoke A.
AU - Sokhela, Mxolisi K.
AU - Koorbanally, Neil A.
AU - Islam, Md Shahidul
N1 - Publisher Copyright:
© 2017 Elsevier Masson SAS
PY - 2017/12
Y1 - 2017/12
N2 - The antioxidative and antidiabetic effects and toxicity of caffeine-rich infusion of Cola nitida were investigated using in vitro, ex vivo and in silico models. C. nitida was infused in boiling water and allowed to cool before concentrating at <50 °C. HPLC analysis of the infusion revealed a caffeine content of 80.08%. The infusion showed potent in vitro antioxidant activity by significantly (p < 0.05) scavenging 2,2′-diphenyl-1-picrylhydrazyl (DPPH). It significantly (p < 0.05) inhibited α-glucosidase and α-amylase activities. Treatment of Fe2+ induced oxidative hepatic tissues with the infusion led to increase Superoxide Dismutase (SOD) and catalase activities, and glutathione (GSH) level as well as decreased malondialdehyde (MDA) level. FTIR spectroscopy of hepatic metabolite revealed restoration of oxidative–induced depleted functional groups by the infusion. LC–MS analysis of the metabolite also revealed restoration of most depleted metabolites with concomitant generation of 4-O-Methylgallic, (-)-Epicatechin sulfate, L-Arginine, L-tyrosine, Citric acid and Decanoic acid in infusion-treated tissues. Pathway analysis of the identified metabolites revealed the presence of 21 metabolic pathways involved in normal hepatic tissues, 12 in oxidative injured tissues and 17 in the treated tissues. Treatment with the infusion restored 4 metabolic pathways common to the normal tissue and further activated 4 additional pathways. Prediction of oral toxicity of caffeine showed it to belong to class 3, with a LD50 of 127 mg/kg. Its toxicity target was predicted as Adenosine Receptor A2a. It was also predicted to be an inhibitor of CYP1A2. These results suggest the antioxidative and antidiabetic properties of C. nitida infusion, with caffeine as the major constituent.
AB - The antioxidative and antidiabetic effects and toxicity of caffeine-rich infusion of Cola nitida were investigated using in vitro, ex vivo and in silico models. C. nitida was infused in boiling water and allowed to cool before concentrating at <50 °C. HPLC analysis of the infusion revealed a caffeine content of 80.08%. The infusion showed potent in vitro antioxidant activity by significantly (p < 0.05) scavenging 2,2′-diphenyl-1-picrylhydrazyl (DPPH). It significantly (p < 0.05) inhibited α-glucosidase and α-amylase activities. Treatment of Fe2+ induced oxidative hepatic tissues with the infusion led to increase Superoxide Dismutase (SOD) and catalase activities, and glutathione (GSH) level as well as decreased malondialdehyde (MDA) level. FTIR spectroscopy of hepatic metabolite revealed restoration of oxidative–induced depleted functional groups by the infusion. LC–MS analysis of the metabolite also revealed restoration of most depleted metabolites with concomitant generation of 4-O-Methylgallic, (-)-Epicatechin sulfate, L-Arginine, L-tyrosine, Citric acid and Decanoic acid in infusion-treated tissues. Pathway analysis of the identified metabolites revealed the presence of 21 metabolic pathways involved in normal hepatic tissues, 12 in oxidative injured tissues and 17 in the treated tissues. Treatment with the infusion restored 4 metabolic pathways common to the normal tissue and further activated 4 additional pathways. Prediction of oral toxicity of caffeine showed it to belong to class 3, with a LD50 of 127 mg/kg. Its toxicity target was predicted as Adenosine Receptor A2a. It was also predicted to be an inhibitor of CYP1A2. These results suggest the antioxidative and antidiabetic properties of C. nitida infusion, with caffeine as the major constituent.
KW - Antioxidative
KW - Cola nitida
KW - Kola nuts
KW - Metabolomics
KW - Type 2 diabetes
UR - https://www.scopus.com/pages/publications/85037988690
U2 - 10.1016/j.biopha.2017.11.120
DO - 10.1016/j.biopha.2017.11.120
M3 - Article
C2 - 29223552
AN - SCOPUS:85037988690
SN - 0753-3322
VL - 96
SP - 1065
EP - 1074
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
ER -